Division of Nephrology and Hypertension, Department of Medicine, Integrated Research and Treatment Center Transplantation (IFB-Tx) Hannover, Hannover Medical School, Hanover, Germany.
J Hypertens. 2011 Dec;29(12):2283-94. doi: 10.1097/HJH.0b013e32834bd1e7.
Arterial hypertension is frequently encountered after renal transplantation and is associated not only with increased cardiovascular complications but also with decreased allograft survival. Adequate blood pressure control is, thus, as essential as immunologic surveillance for the long-term transplant care. Nevertheless, randomized control trials assessing treatment targets in these patients are not available and most of the evidence comes from studies in patients with native chronic kidney disease or the general population. In this regard, the renal transplant recipient is treated according to recommendations that are applicable to nontransplanted individuals at high cardiovascular risk. However, the accepted treatment targets for the nontransplanted population are recently being disputed and this makes the management of posttransplant hypertension even more challenging.
动脉高血压在肾移植后经常发生，不仅与心血管并发症的增加有关，还与移植物存活率的降低有关。因此，充分的血压控制与免疫监测对于长期的移植护理一样重要。然而，评估这些患者治疗目标的随机对照试验尚不可用，大多数证据来自于对患有原发性慢性肾脏病或普通人群的患者的研究。在这方面，根据适用于心血管风险高的非移植个体的建议对肾移植受者进行治疗。然而，最近对非移植人群的可接受治疗目标提出了质疑，这使得移植后高血压的治疗更加具有挑战性。
